-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 17 news, the biological products sector had the largest gains
.
Among them, Watson Biotech rose by more than 8%, Zhifei Bio by more than 6%, and Cansino Bio by more than 5%.
In addition, China National Biopharmaceutical, CSPC, Cinda Bio, Fosun Pharma, Changchun High-tech, etc.
have followed the increase.
.
Judging from the performance of the biological products segment in the first half of the year, according to Flush iFinD data, the biological products segment performed outstandingly in the first half of this year.
Revenue maintained a sustained and stable growth trend, achieving 77.
99 billion yuan, a year-on-year increase of 35.
52%.
It is worth mentioning that this growth rate is much higher than the overall growth rate of 24.
04% in the pharmaceutical and biological industry; net profit has maintained a trend of volatility and upward development, achieving net profit attributable to shareholders of listed companies at 18.
616 billion yuan, a year-on-year increase of 101.
41%
.
In addition, in the first half of the year, the gross profit margin of the biological products segment was also relatively high
.
Flush iFinD data shows that in the first half of this year, the overall gross profit margin of the pharmaceutical and biological industry was 35.
36%, a year-on-year increase of 0.
01%
.
Among them, the gross profit rate of biological products was 58.
87%, which was higher than the overall gross profit rate of the industry.
In the first half of this year, the gross profit rate of biological products increased by 2.
92 percentage points year-on-year
.
The industry believes that the outstanding performance of the biological products sector in the first half of the year was mainly due to the large volume of vaccines and the rebound in blood products and biological drugs
.
Among them, the performance of vaccine industry companies in the first half of the year was obviously good, becoming an important driving force for the growth of the biological products sector
.
For example, according to Cansino’s financial report data released on August 30, the company achieved operating income of 2.
061 billion yuan in the first half of this year, an increase of 51057.
67% year-on-year; Surplus
.
From the company’s interpretation of performance changes, it is mainly vaccine products that have had a positive impact on the company’s main business income and the net profit attributable to the owners of the parent company.
.
Watson Biological released the 2021 semi-annual report on the evening of August 27, stating that the company achieved double growth in revenue and profits in the first half of the year, of which operating income was 1.
350 billion yuan in the first half of the year, a year-on-year increase of 135.
37%; non-net profit attributable to shareholders of listed companies was 2.
40 Billion yuan, a year-on-year increase of 318.
21%
.
Regarding performance growth, the company stated in the semi-annual report that, on the one hand, the company increased its market development efforts in the first half of the year to achieve steady growth in sales and operating income of independent vaccine products; on the other hand, the company’s product listed in December 2019 was 13-price pneumonia The market demand for the coccal polysaccharide conjugate vaccine "Woanxin" continues to improve
.
The company also revealed that in the second half of 2021, the company will continue to do a good job in the production and sales of self-produced vaccine products, continue to promote the development and industrialization of new products, and further increase its strength to accelerate the implementation and landing of the comprehensive internationalization strategy
.
At the same time, pay close attention to the situation of the international epidemic and speed up the clinical and industrialization of vaccines
.
Looking forward to the future development prospects of the biological products industry, the industry believes that with the increase in residents' disposable income, the increase in health prevention awareness, and the country’s increasing investment in the biological products industry, the manufacturing demand for biological and biochemical products will continue.
Increase
.
It is estimated that China's biological products market will grow by about 20% every year, and it may exceed 600 billion yuan by 2023
.
However, it must be noted that foreign investment is gradually increasing, coupled with the advancement of a series of domestic regulatory reforms, the industry is facing a reshuffle, and only companies with strong innovative R&D capabilities can achieve rapid development
.
Industry recommendations can focus on industry giants, as well as companies with long-term growth and good profit models
.
.
Among them, Watson Biotech rose by more than 8%, Zhifei Bio by more than 6%, and Cansino Bio by more than 5%.
In addition, China National Biopharmaceutical, CSPC, Cinda Bio, Fosun Pharma, Changchun High-tech, etc.
have followed the increase.
.
Judging from the performance of the biological products segment in the first half of the year, according to Flush iFinD data, the biological products segment performed outstandingly in the first half of this year.
Revenue maintained a sustained and stable growth trend, achieving 77.
99 billion yuan, a year-on-year increase of 35.
52%.
It is worth mentioning that this growth rate is much higher than the overall growth rate of 24.
04% in the pharmaceutical and biological industry; net profit has maintained a trend of volatility and upward development, achieving net profit attributable to shareholders of listed companies at 18.
616 billion yuan, a year-on-year increase of 101.
41%
.
In addition, in the first half of the year, the gross profit margin of the biological products segment was also relatively high
.
Flush iFinD data shows that in the first half of this year, the overall gross profit margin of the pharmaceutical and biological industry was 35.
36%, a year-on-year increase of 0.
01%
.
Among them, the gross profit rate of biological products was 58.
87%, which was higher than the overall gross profit rate of the industry.
In the first half of this year, the gross profit rate of biological products increased by 2.
92 percentage points year-on-year
.
The industry believes that the outstanding performance of the biological products sector in the first half of the year was mainly due to the large volume of vaccines and the rebound in blood products and biological drugs
.
Among them, the performance of vaccine industry companies in the first half of the year was obviously good, becoming an important driving force for the growth of the biological products sector
.
For example, according to Cansino’s financial report data released on August 30, the company achieved operating income of 2.
061 billion yuan in the first half of this year, an increase of 51057.
67% year-on-year; Surplus
.
From the company’s interpretation of performance changes, it is mainly vaccine products that have had a positive impact on the company’s main business income and the net profit attributable to the owners of the parent company.
.
Watson Biological released the 2021 semi-annual report on the evening of August 27, stating that the company achieved double growth in revenue and profits in the first half of the year, of which operating income was 1.
350 billion yuan in the first half of the year, a year-on-year increase of 135.
37%; non-net profit attributable to shareholders of listed companies was 2.
40 Billion yuan, a year-on-year increase of 318.
21%
.
Regarding performance growth, the company stated in the semi-annual report that, on the one hand, the company increased its market development efforts in the first half of the year to achieve steady growth in sales and operating income of independent vaccine products; on the other hand, the company’s product listed in December 2019 was 13-price pneumonia The market demand for the coccal polysaccharide conjugate vaccine "Woanxin" continues to improve
.
The company also revealed that in the second half of 2021, the company will continue to do a good job in the production and sales of self-produced vaccine products, continue to promote the development and industrialization of new products, and further increase its strength to accelerate the implementation and landing of the comprehensive internationalization strategy
.
At the same time, pay close attention to the situation of the international epidemic and speed up the clinical and industrialization of vaccines
.
Looking forward to the future development prospects of the biological products industry, the industry believes that with the increase in residents' disposable income, the increase in health prevention awareness, and the country’s increasing investment in the biological products industry, the manufacturing demand for biological and biochemical products will continue.
Increase
.
It is estimated that China's biological products market will grow by about 20% every year, and it may exceed 600 billion yuan by 2023
.
However, it must be noted that foreign investment is gradually increasing, coupled with the advancement of a series of domestic regulatory reforms, the industry is facing a reshuffle, and only companies with strong innovative R&D capabilities can achieve rapid development
.
Industry recommendations can focus on industry giants, as well as companies with long-term growth and good profit models
.
